Lifecore Biomedical, Inc. (NASDAQ: LFCR) Stock Competitors & Peer Comparison
See LFCR's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for LFCR and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LFCR | $4.54 | -4.02% | 177M | -4.41 | -$1.07 | N/A |
| TAK | $17.38 | -0.09% | 56.1B | 12.68 | $1.39 | +3.58% |
| TEVA | $36.52 | +0.00% | 42.8B | 12.55 | $2.93 | N/A |
| HLN | $9.62 | -1.83% | 42.7B | 18.09 | $0.54 | +1.27% |
| VTRS | $16.22 | +1.09% | 18.9B | 6.44 | $2.52 | +2.96% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $23.50 | +4.38% | 11.8B | 22.33 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $12.19 | -1.89% | 10.2B | 20.11 | $0.61 | +0.68% |
| LNTH | $100.86 | -0.08% | 6.6B | 16.97 | $5.95 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
LFCR vs TAK Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, TAK has a market cap of 56.1B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while TAK trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas TAK's P/E ratio is 12.68. In terms of profitability, LFCR's ROE is -2.51%, compared to TAK's ROE of +0.02%. Regarding short-term risk, LFCR is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
LFCR vs TEVA Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, TEVA has a market cap of 42.8B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while TEVA trades at $36.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas TEVA's P/E ratio is 12.55. In terms of profitability, LFCR's ROE is -2.51%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, LFCR is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check TEVA's competition here
Haleon plc (NYSE: HLN)
LFCR vs HLN Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, HLN has a market cap of 42.7B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while HLN trades at $9.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas HLN's P/E ratio is 18.09. In terms of profitability, LFCR's ROE is -2.51%, compared to HLN's ROE of +0.17%. Regarding short-term risk, LFCR is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check HLN's competition here
Viatris Inc. (NASDAQ: VTRS)
LFCR vs VTRS Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, VTRS has a market cap of 18.9B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while VTRS trades at $16.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas VTRS's P/E ratio is 6.44. In terms of profitability, LFCR's ROE is -2.51%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, LFCR is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
LFCR vs ITCI Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas ITCI's P/E ratio is -180.64. In terms of profitability, LFCR's ROE is -2.51%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, LFCR is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
LFCR vs ELAN Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, ELAN has a market cap of 11.8B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while ELAN trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas ELAN's P/E ratio is 22.33. In terms of profitability, LFCR's ROE is -2.51%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, LFCR is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
LFCR vs CTLT Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas CTLT's P/E ratio is -27.84. In terms of profitability, LFCR's ROE is -2.51%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, LFCR is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
LFCR vs RDY Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, RDY has a market cap of 10.2B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while RDY trades at $12.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas RDY's P/E ratio is 20.11. In terms of profitability, LFCR's ROE is -2.51%, compared to RDY's ROE of +0.09%. Regarding short-term risk, LFCR is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
LFCR vs LNTH Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while LNTH trades at $100.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas LNTH's P/E ratio is 16.97. In terms of profitability, LFCR's ROE is -2.51%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, LFCR is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
LFCR vs AMRX Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, AMRX has a market cap of 5.8B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while AMRX trades at $18.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas AMRX's P/E ratio is 20.17. In terms of profitability, LFCR's ROE is -2.51%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, LFCR is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
LFCR vs INDV Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, INDV has a market cap of 4.9B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while INDV trades at $39.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas INDV's P/E ratio is 10.69. In terms of profitability, LFCR's ROE is -2.51%, compared to INDV's ROE of -2.16%. Regarding short-term risk, LFCR is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
LFCR vs SUPN Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while SUPN trades at $48.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas SUPN's P/E ratio is 15.77. In terms of profitability, LFCR's ROE is -2.51%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, LFCR is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
LFCR vs RGC Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while RGC trades at $5.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas RGC's P/E ratio is -383.80. In terms of profitability, LFCR's ROE is -2.51%, compared to RGC's ROE of -2.32%. Regarding short-term risk, LFCR is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
LFCR vs BHC Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while BHC trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas BHC's P/E ratio is 1.66. In terms of profitability, LFCR's ROE is -2.51%, compared to BHC's ROE of +0.89%. Regarding short-term risk, LFCR is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
LFCR vs DCPH Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas DCPH's P/E ratio is -11.58. In terms of profitability, LFCR's ROE is -2.51%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, LFCR is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
LFCR vs HCM Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while HCM trades at $12.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas HCM's P/E ratio is 4.57. In terms of profitability, LFCR's ROE is -2.51%, compared to HCM's ROE of +0.01%. Regarding short-term risk, LFCR is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
LFCR vs AVDL Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, LFCR's ROE is -2.51%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, LFCR is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
LFCR vs EMBCV Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas EMBCV's P/E ratio is N/A. In terms of profitability, LFCR's ROE is -2.51%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, LFCR is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
LFCR vs DVAX Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas DVAX's P/E ratio is -41.89. In terms of profitability, LFCR's ROE is -2.51%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, LFCR is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check DVAX's competition here
Perrigo Company plc (NYSE: PRGO)
LFCR vs PRGO Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while PRGO trades at $13.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas PRGO's P/E ratio is 5.22. In terms of profitability, LFCR's ROE is -2.51%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, LFCR is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check PRGO's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
LFCR vs ANIP Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while ANIP trades at $77.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas ANIP's P/E ratio is 9.31. In terms of profitability, LFCR's ROE is -2.51%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, LFCR is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
LFCR vs TARO Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas TARO's P/E ratio is 30.05. In terms of profitability, LFCR's ROE is -2.51%, compared to TARO's ROE of +0.03%. Regarding short-term risk, LFCR is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check TARO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
LFCR vs ETON Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while ETON trades at $60.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas ETON's P/E ratio is -840.86. In terms of profitability, LFCR's ROE is -2.51%, compared to ETON's ROE of +0.40%. Regarding short-term risk, LFCR is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check ETON's competition here
Harrow Health, Inc. (NASDAQ: HROW)
LFCR vs HROW Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while HROW trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas HROW's P/E ratio is 444.78. In terms of profitability, LFCR's ROE is -2.51%, compared to HROW's ROE of -1.04%. Regarding short-term risk, LFCR is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check HROW's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
LFCR vs PAHC Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while PAHC trades at $34.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas PAHC's P/E ratio is 11.73. In terms of profitability, LFCR's ROE is -2.51%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, LFCR is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check PAHC's competition here
Alvotech (NASDAQ: ALVO)
LFCR vs ALVO Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, ALVO has a market cap of 1.4B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while ALVO trades at $3.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas ALVO's P/E ratio is -11.93. In terms of profitability, LFCR's ROE is -2.51%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, LFCR is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check ALVO's competition here
Cronos Group Inc. (NASDAQ: CRON)
LFCR vs CRON Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while CRON trades at $3.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas CRON's P/E ratio is 29.82. In terms of profitability, LFCR's ROE is -2.51%, compared to CRON's ROE of +0.06%. Regarding short-term risk, LFCR is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
LFCR vs AMPH Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, AMPH has a market cap of 922M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while AMPH trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas AMPH's P/E ratio is 7.14. In terms of profitability, LFCR's ROE is -2.51%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, LFCR is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check AMPH's competition here
PetIQ, Inc. (NASDAQ: PETQ)
LFCR vs PETQ Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas PETQ's P/E ratio is 83.73. In terms of profitability, LFCR's ROE is -2.51%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, LFCR is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
LFCR vs COLL Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, COLL has a market cap of 915.6M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while COLL trades at $28.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas COLL's P/E ratio is 3.54. In terms of profitability, LFCR's ROE is -2.51%, compared to COLL's ROE of +0.16%. Regarding short-term risk, LFCR is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check COLL's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
LFCR vs PCRX Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, PCRX has a market cap of 904.7M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while PCRX trades at $23.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas PCRX's P/E ratio is 8.85. In terms of profitability, LFCR's ROE is -2.51%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, LFCR is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check PCRX's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
LFCR vs IRWD Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, IRWD has a market cap of 709.5M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while IRWD trades at $4.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas IRWD's P/E ratio is 5.53. In terms of profitability, LFCR's ROE is -2.51%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, LFCR is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
LFCR vs EVO Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, EVO has a market cap of 696.3M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while EVO trades at $1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas EVO's P/E ratio is -2.77. In terms of profitability, LFCR's ROE is -2.51%, compared to EVO's ROE of -0.26%. Regarding short-term risk, LFCR is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check EVO's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
LFCR vs BDSI Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas BDSI's P/E ratio is 6.82. In terms of profitability, LFCR's ROE is -2.51%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, LFCR is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check BDSI's competition here
Evolus, Inc. (NASDAQ: EOLS)
LFCR vs EOLS Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, EOLS has a market cap of 537M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while EOLS trades at $8.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas EOLS's P/E ratio is -25.82. In terms of profitability, LFCR's ROE is -2.51%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, LFCR is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
LFCR vs AQST Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, AQST has a market cap of 533.2M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while AQST trades at $4.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas AQST's P/E ratio is -6.97. In terms of profitability, LFCR's ROE is -2.51%, compared to AQST's ROE of +2.44%. Regarding short-term risk, LFCR is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check AQST's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
LFCR vs TLRY Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, TLRY has a market cap of 522.3M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while TLRY trades at $4.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas TLRY's P/E ratio is -4.31. In terms of profitability, LFCR's ROE is -2.51%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, LFCR is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check TLRY's competition here
Kamada Ltd. (NASDAQ: KMDA)
LFCR vs KMDA Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, KMDA has a market cap of 437.3M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while KMDA trades at $7.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas KMDA's P/E ratio is 21.66. In terms of profitability, LFCR's ROE is -2.51%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, LFCR is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
LFCR vs CGC Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, CGC has a market cap of 424.3M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while CGC trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas CGC's P/E ratio is -0.60. In terms of profitability, LFCR's ROE is -2.51%, compared to CGC's ROE of -0.33%. Regarding short-term risk, LFCR is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
LFCR vs TKNO Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, TKNO has a market cap of 390.8M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while TKNO trades at $7.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas TKNO's P/E ratio is -23.52. In terms of profitability, LFCR's ROE is -2.51%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, LFCR is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check TKNO's competition here
Embecta Corp. (NASDAQ: EMBC)
LFCR vs EMBC Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, EMBC has a market cap of 302.6M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while EMBC trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas EMBC's P/E ratio is 1.96. In terms of profitability, LFCR's ROE is -2.51%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, LFCR is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check EMBC's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
LFCR vs ALIM Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas ALIM's P/E ratio is 5.28. In terms of profitability, LFCR's ROE is -2.51%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, LFCR is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
LFCR vs LNDC Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas LNDC's P/E ratio is -4.04. In terms of profitability, LFCR's ROE is -2.51%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, LFCR is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check LNDC's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
LFCR vs ORGO Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, ORGO has a market cap of 230.3M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while ORGO trades at $1.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas ORGO's P/E ratio is 59.67. In terms of profitability, LFCR's ROE is -2.51%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, LFCR is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
LFCR vs TYHT Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas TYHT's P/E ratio is -1.61. In terms of profitability, LFCR's ROE is -2.51%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, LFCR is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check TYHT's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
LFCR vs ACB Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, ACB has a market cap of 227.9M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while ACB trades at $3.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas ACB's P/E ratio is -7.51. In terms of profitability, LFCR's ROE is -2.51%, compared to ACB's ROE of -0.21%. Regarding short-term risk, LFCR is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check ACB's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
LFCR vs SIGA Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, SIGA has a market cap of 215.2M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while SIGA trades at $2.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas SIGA's P/E ratio is 11.11. In terms of profitability, LFCR's ROE is -2.51%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, LFCR is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check SIGA's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
LFCR vs CRDL Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, CRDL has a market cap of 207.5M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while CRDL trades at $1.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas CRDL's P/E ratio is -6.41. In terms of profitability, LFCR's ROE is -2.51%, compared to CRDL's ROE of -2.31%. Regarding short-term risk, LFCR is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check CRDL's competition here
Journey Medical Corporation (NASDAQ: DERM)
LFCR vs DERM Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, DERM has a market cap of 183M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while DERM trades at $6.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas DERM's P/E ratio is -17.97. In terms of profitability, LFCR's ROE is -2.51%, compared to DERM's ROE of -0.20%. Regarding short-term risk, LFCR is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check DERM's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
LFCR vs REPH Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas REPH's P/E ratio is -8.04. In terms of profitability, LFCR's ROE is -2.51%, compared to REPH's ROE of -0.22%. Regarding short-term risk, LFCR is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check REPH's competition here
Organigram Global Inc. (NASDAQ: OGI)
LFCR vs OGI Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, OGI has a market cap of 173.2M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while OGI trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas OGI's P/E ratio is -4.73. In terms of profitability, LFCR's ROE is -2.51%, compared to OGI's ROE of +0.21%. Regarding short-term risk, LFCR is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check OGI's competition here
Theratechnologies Inc. (NASDAQ: THTX)
LFCR vs THTX Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas THTX's P/E ratio is -28.83. In terms of profitability, LFCR's ROE is -2.51%, compared to THTX's ROE of +0.17%. Regarding short-term risk, LFCR is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
LFCR vs ASRT Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas ASRT's P/E ratio is -7.10. In terms of profitability, LFCR's ROE is -2.51%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, LFCR is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check ASRT's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
LFCR vs CPIX Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, CPIX has a market cap of 116.7M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while CPIX trades at $7.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas CPIX's P/E ratio is -19.47. In terms of profitability, LFCR's ROE is -2.51%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, LFCR is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
LFCR vs SCTL Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas SCTL's P/E ratio is -7.86. In terms of profitability, LFCR's ROE is -2.51%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, LFCR is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
LFCR vs BGM Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, BGM has a market cap of 110.8M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while BGM trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas BGM's P/E ratio is -1.00. In terms of profitability, LFCR's ROE is -2.51%, compared to BGM's ROE of -0.07%. Regarding short-term risk, LFCR is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
LFCR vs PROC Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas PROC's P/E ratio is 1.53. In terms of profitability, LFCR's ROE is -2.51%, compared to PROC's ROE of -2.22%. Regarding short-term risk, LFCR is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
LFCR vs OPTN Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas OPTN's P/E ratio is -4.42. In terms of profitability, LFCR's ROE is -2.51%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, LFCR is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
LFCR vs ZOM Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas ZOM's P/E ratio is -1.62. In terms of profitability, LFCR's ROE is -2.51%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, LFCR is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
LFCR vs GRVI Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas GRVI's P/E ratio is 26.05. In terms of profitability, LFCR's ROE is -2.51%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, LFCR is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
LFCR vs ZYBT Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, ZYBT has a market cap of 75.4M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while ZYBT trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas ZYBT's P/E ratio is -7.23. In terms of profitability, LFCR's ROE is -2.51%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, LFCR is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
LFCR vs ZYNE Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, LFCR's ROE is -2.51%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, LFCR is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
LFCR vs SSIC Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas SSIC's P/E ratio is 11.93. In terms of profitability, LFCR's ROE is -2.51%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, LFCR is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check SSIC's competition here
Talphera, Inc. (NASDAQ: TLPH)
LFCR vs TLPH Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, TLPH has a market cap of 63.8M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while TLPH trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas TLPH's P/E ratio is -3.97. In terms of profitability, LFCR's ROE is -2.51%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, LFCR is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check TLPH's competition here
The Valens Company Inc. (NASDAQ: VLNS)
LFCR vs VLNS Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas VLNS's P/E ratio is -1.03. In terms of profitability, LFCR's ROE is -2.51%, compared to VLNS's ROE of N/A. Regarding short-term risk, LFCR is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
LFCR vs DRRX Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas DRRX's P/E ratio is -4.44. In terms of profitability, LFCR's ROE is -2.51%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, LFCR is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
LFCR vs INCR Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, INCR has a market cap of 55.1M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while INCR trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas INCR's P/E ratio is -2.15. In terms of profitability, LFCR's ROE is -2.51%, compared to INCR's ROE of -0.09%. Regarding short-term risk, LFCR is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
LFCR vs JUPW Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas JUPW's P/E ratio is -2.41. In terms of profitability, LFCR's ROE is -2.51%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, LFCR is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check JUPW's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
LFCR vs CPHI Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, CPHI has a market cap of 45.2M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while CPHI trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas CPHI's P/E ratio is -1.74. In terms of profitability, LFCR's ROE is -2.51%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, LFCR is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check CPHI's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
LFCR vs QLI Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas QLI's P/E ratio is -4.92. In terms of profitability, LFCR's ROE is -2.51%, compared to QLI's ROE of -0.16%. Regarding short-term risk, LFCR is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
LFCR vs HEXO Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas HEXO's P/E ratio is -0.26. In terms of profitability, LFCR's ROE is -2.51%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, LFCR is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
LFCR vs RMTI Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, RMTI has a market cap of 29.2M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while RMTI trades at $7.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas RMTI's P/E ratio is -7.06. In terms of profitability, LFCR's ROE is -2.51%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, LFCR is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
LFCR vs AYTU Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, AYTU has a market cap of 25.5M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while AYTU trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas AYTU's P/E ratio is -1.24. In terms of profitability, LFCR's ROE is -2.51%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, LFCR is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
LFCR vs TXMD Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, TXMD has a market cap of 24M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while TXMD trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas TXMD's P/E ratio is 105.45. In terms of profitability, LFCR's ROE is -2.51%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, LFCR is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
LFCR vs CYTH Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas CYTH's P/E ratio is -0.80. In terms of profitability, LFCR's ROE is -2.51%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, LFCR is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
LFCR vs EVOK Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas EVOK's P/E ratio is -7.97. In terms of profitability, LFCR's ROE is -2.51%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, LFCR is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
LFCR vs OPTH Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, OPTH has a market cap of 15.5M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while OPTH trades at $4.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas OPTH's P/E ratio is -17.60. In terms of profitability, LFCR's ROE is -2.51%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, LFCR is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
LFCR vs ACRX Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas ACRX's P/E ratio is -0.31. In terms of profitability, LFCR's ROE is -2.51%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, LFCR is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check ACRX's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
LFCR vs BFRIW Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, BFRIW has a market cap of 14.2M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while BFRIW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, LFCR's ROE is -2.51%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, LFCR is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check BFRIW's competition here
Cosmos Health Inc. (NASDAQ: COSM)
LFCR vs COSM Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, COSM has a market cap of 11.9M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while COSM trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas COSM's P/E ratio is -0.30. In terms of profitability, LFCR's ROE is -2.51%, compared to COSM's ROE of -0.96%. Regarding short-term risk, LFCR is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
LFCR vs AGRX Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas AGRX's P/E ratio is -0.89. In terms of profitability, LFCR's ROE is -2.51%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, LFCR is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
LFCR vs NLTX Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas NLTX's P/E ratio is -0.28. In terms of profitability, LFCR's ROE is -2.51%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, LFCR is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
LFCR vs LCI Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas LCI's P/E ratio is -0.04. In terms of profitability, LFCR's ROE is -2.51%, compared to LCI's ROE of +1.66%. Regarding short-term risk, LFCR is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
LFCR vs ADMP Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas ADMP's P/E ratio is -0.08. In terms of profitability, LFCR's ROE is -2.51%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, LFCR is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check ADMP's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
LFCR vs GELS Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, GELS has a market cap of 5.3M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while GELS trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas GELS's P/E ratio is -1.16. In terms of profitability, LFCR's ROE is -2.51%, compared to GELS's ROE of -0.25%. Regarding short-term risk, LFCR is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check GELS's competition here
cbdMD, Inc. (AMEX: YCBD)
LFCR vs YCBD Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, YCBD has a market cap of 5.2M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while YCBD trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas YCBD's P/E ratio is -1.22. In terms of profitability, LFCR's ROE is -2.51%, compared to YCBD's ROE of -0.58%. Regarding short-term risk, LFCR is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check YCBD's competition here
Mallinckrodt plc (AMEX: MNK)
LFCR vs MNK Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas MNK's P/E ratio is -0.44. In terms of profitability, LFCR's ROE is -2.51%, compared to MNK's ROE of -0.36%. Regarding short-term risk, LFCR is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
LFCR vs FLGC Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas FLGC's P/E ratio is -0.19. In terms of profitability, LFCR's ROE is -2.51%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, LFCR is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
LFCR vs UPC Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, UPC has a market cap of 3.6M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while UPC trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas UPC's P/E ratio is -0.70. In terms of profitability, LFCR's ROE is -2.51%, compared to UPC's ROE of -0.03%. Regarding short-term risk, LFCR is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
LFCR vs SBFM Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, SBFM has a market cap of 2.7M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while SBFM trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas SBFM's P/E ratio is -0.19. In terms of profitability, LFCR's ROE is -2.51%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, LFCR is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
LFCR vs PLXP Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas PLXP's P/E ratio is -0.22. In terms of profitability, LFCR's ROE is -2.51%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, LFCR is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check PLXP's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
LFCR vs SHPH Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, SHPH has a market cap of 2.4M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while SHPH trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas SHPH's P/E ratio is -0.19. In terms of profitability, LFCR's ROE is -2.51%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, LFCR is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check SHPH's competition here
Athenex, Inc. (NASDAQ: ATNX)
LFCR vs ATNX Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas ATNX's P/E ratio is -0.02. In terms of profitability, LFCR's ROE is -2.51%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, LFCR is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check ATNX's competition here
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
LFCR vs SXTC Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, SXTC has a market cap of 2.2M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while SXTC trades at $3.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas SXTC's P/E ratio is 1.51. In terms of profitability, LFCR's ROE is -2.51%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, LFCR is less volatile compared to SXTC. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check SXTC's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
LFCR vs SNOA Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, SNOA has a market cap of 2.2M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while SNOA trades at $1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas SNOA's P/E ratio is -1.10. In terms of profitability, LFCR's ROE is -2.51%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, LFCR is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check SNOA's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
LFCR vs PROCW Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas PROCW's P/E ratio is N/A. In terms of profitability, LFCR's ROE is -2.51%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, LFCR is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check PROCW's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
LFCR vs RDHL Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, RDHL has a market cap of 1.8M. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while RDHL trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas RDHL's P/E ratio is 0.12. In terms of profitability, LFCR's ROE is -2.51%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, LFCR is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check RDHL's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
LFCR vs YCBD-PA Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, LFCR's ROE is -2.51%, compared to YCBD-PA's ROE of -0.58%. Regarding short-term risk, LFCR is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for LFCR.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
LFCR vs CYTHW Comparison August 2026
Lifecore Biomedical, Inc. (NASDAQ: LFCR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LFCR stands at 177M. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, LFCR is priced at $4.54 on the NASDAQ, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LFCR currently has a P/E ratio of -4.41, whereas CYTHW's P/E ratio is N/A. In terms of profitability, LFCR's ROE is -2.51%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, LFCR is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for LFCR.Check CYTHW's competition here